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Introduction
Type-1 diabetes mellitus (T1DM) is a disease state in which
the immune system of an individual destroys the β cells of
the pancreas consequently affecting insulin secretion, result-
ing in raised glucose levels.1 The incidence of T1DM varies
widely across the world, with age-adjusted incidences rang-
ing from 0.1/100,000 individuals per year in China and
Venezuela to 36.5 and 36.8/100,000 individuals per year in
Finland and Sardinia, respectively.2 If T1DM is not correctly
managed, the reduced insulin concentration in the blood can
cause death, while the resultant elevated glucose concentra-
tionwill increase the riskofmicrovascular complications and
the risk of developing long-term vascular diseases.3 Individ-
uals with T1DM are estimated to have a standardized mor-
tality ratio attributable to cardiovascular diseases of 5.7 for
men and 11.3 for women compared with healthy individua-
ls.3,4 Despite the known increased risk of cardiovascular
disease in individuals with T1DM, the pathophysiology
underlying this relationship is not well understood.
Magnesium is an essential macronutrient and in its ionic
form (Mg2þ) is essential for hemostasis and coagulation.1,5
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Abstract Individuals with type-1 diabetes mellitus (T1DM) have a higher risk of thrombosis and low
plasma magnesium concentrations. As magnesium is a known regulator of fibrin network
formation, we investigated potential associations between fibrin clot properties and
plasma magnesium concentrations in 45 individuals with T1DM and 47 age- and sex-
matched controls without diabetes. Fibrin clot characteristics were assessed using a
validated turbidimetric assay and associations with plasma magnesium concentration
were examined. Plasma concentrations of fibrinogen, plasminogen activator inhibitor-1
(PAI-1), and lipids were measured and fibrin fiber diameters assessed using scanning
electron microscopy. Fibrin clot maximum absorbance was unchanged in subjects with
T1DMcomparedwith controls, while lysis timewas prolonged (p¼0.0273). No differences
in fibrin fiber diameters or in lipid profile were observed betweenT1DM and controls. PAI-1
concentration was lower in the T1DM group compared with the controls (p¼ 0.0232) and
positively correlated with lysis time (p¼ 0.0023). Plasma magnesium concentration was
lower in the T1DM group compared with controls (p<0.0001). Magnesium concentration
negatively correlated with clot maximum absorbance (p¼0.0215) and lysis time
(p¼0.0464). A turbidimetric fibrin clot lysis assay performed in a purified system that
included PAI-1 and 0 to 3.2mM Mg2þ showed a shortening of lysis time with increasing
Mg2þ concentrations (p¼ 0.0004). Our findings reveal that plasmamagnesium concentra-
tion is associated with changes in fibrin clot and lysis parameters.
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Mg2þ is present in the blood at a concentration of 0.8 to
1.2mM,1,5 and is a required cofactor in approximately 600
enzymes and an activator for a further approximately 200
enzymes.6 Mg2þ is known to strongly influence the coagula-
tion cascade. Indeed, addition of an excess of Mg2þ results in
an inability of blood to clot,7 and although it is not used
routinely, magnesium sulfate has been successfully used
during blood collection as an alternative to citrate and
ethylenediaminetetraacetic acid.8 Mg2þ homeostasis and
the insulin concentration in the blood are closely linked.
Notably, insulin affects tubular reabsorption of Mg2þ from
the blood by the kidney, while Mg2þ is involved in energy
metabolism and the regulation of insulin release.9 In addi-
tion, magnesium deficiency in humans and animals can
cause hypercoagulablity,10 while magnesium deficiency in
swine has been shown to lead to reduced plasma concen-
trations of coagulatory molecules including antithrombin,
thromboxane, protein C, and endothelin-1.11
In a recent study examining plasma concentrations of
different metals in subjects with diabetes, we found that
individuals with T1DM have a reduced plasma magnesium
concentration compared with controls.9 Given that patients
with T1DM have an increased thrombotic risk,12 andMg2þ is
known to play an essential role in coagulation control, we
hypothesized that the lowered plasma magnesium concen-
tration associatedwith T1DMmay affect blood coagulability.
Here, we examine both fibrin clotting and clot lysis in plasma
taken from the same T1DM and control cohort as previously
reported,9 and based on the results explore the relationship
between plasma Mg2þ concentration and measured fibrin
clot and lysis parameters.
Methods
Clinical Sample Collection
IndividualswithT1DMandcontrolswere recruited fromLeeds
Teaching Hospital Trust following approval by the Leeds West
Research Ethics Committee (REC: 09/H1307/12). Written in-
formed consent to participate was obtained. A total of 45
individuals with T1DM and 47 controls were recruited from
Leeds Teaching Hospital Trust. A total number of 92 samples is
enough to detect 29.5% differences in individual fibrin clot
parameters between groups,with a power of 80% (at p<0.05),
given the standard deviation of the studied variable at 50%.
Exclusion criteria included: a history of acute coronary syn-
drome or stroke within 3 months of enrolment, prior treat-
ment with aspirin, clopidogrel, warfarin, or nonsteroidal
antiinflammatory drugs, current treatment with any drug
other than insulin, a history of deep venous thrombosis or
pulmonaryembolismandprevious or current historyof upper
gastrointestinal pathology, malignancy or coagulation disor-
ders. Any individual with abnormal liver function tests (ala-
nine transaminase>3 fold upper limit of normal) or abnormal
thyroid function testswere not included. Finally, patientswith
proteinuria, advanced nephropathy, clinical signs of neuropa-
thy, or retinopathy (except for thosewithbackgroundchanges)
were excluded. Written informed consent was obtained and
baseline fasting blood samples were collected in trisodium
citrate or lithium heparin coated tubes. Plasmawas separated
by centrifugation at 2,400 g for 20minutes at 4°C within
2hours of collection. The samples were snap frozen in liquid
nitrogen and stored at 40°C until analysis.
Plasma Measurement of PAI-1, HbA1c, Lipid, and
Lipoprotein Concentrations
The citrated plasma samples were used to measure the
plasma fibrinogen concentrations using Clauss’s method.
The lithium-heparin plasma samples were used to measure
thehuman serum albumin (HSA) levelswith the bromocresol
purple method using an automated analyzer (Architect;
Abbot Diagnosis, Maidenhead, UK) and to measure the
plasminogen activator inhibitor-1 (PAI-1) concentration
with an enzyme-linked immunosorbent assay and the plas-
ma concentrations of glycated hemoglobin A1c (HbA1c),
triglycerides, cholesterol, high density lipoprotein (HDL),
and low density lipoprotein (LDL) using routine methods.
Total plasma zinc, copper, magnesium, and selenium con-
centrations were previously measured using the lithium-
heparin samples by inductively coupled plasma-mass spec-
trometry on plasma samples (as described by Sobczak et al9).
Turbidimetric Fibrin Clot Formation and Lysis Assays in
Plasma from Subjects with T1DM and Controls
To compare fibrin clot parameters in individuals with T1DM
and controls, turbidimetric assays were performed as previ-
ously described.13,14 Plasma samples from individuals with
T1DM and from controls were thawed in a water bath at 37°C
and centrifuged for 30 seconds at 3,600 g. The samples were
placed into a 96-well plate and then tPA (tissue plasminogen
activator; Technoclone, Vienna, Austria) was added followed
by thrombin (Calbiochem; San Diego, CA, USA) and CaCl2. The
final concentrations were: plasma diluted sixfold in buffer
(50mM Tris, 100mMNaCl, pH 7.4), 3.75mMCaCl2, 0.03 U/mL
thrombin, and 20.8 ng/mL tPA. The absorbance at 340nmwas
read with a Multiskan FC plate reader (Thermo Scientific;
Paisley, UK) every 12seconds at 37°C. Clot formation and lysis
parameters (maximum absorbance and lysis time defined as
the time between maximum clotting and 50% lysis) were
calculated from the resultant data with Prism 7.0 (GraphPad
Software; La Jolla, CA, USA).
Scanning Electron Microscopy
To assess fibrin fiber thickness in T1DM and controls, clots
were formed in duplicate in the pierced lids of 0.6mL centri-
fuge tubes in 45 µL volumes of pooled plasma diluted onefold
in buffer (50mM Tris, 100mM NaCl, pH 7.4). The plasma
samples were pooled from six randomly chosen subjects
from each of the T1DM and control group. Clotting was
induced by addition of 5 µL of 25mM CaCl2 and 5 U/mL
thrombin in buffer (50mM Tris, 100mM NaCl, pH 7.4). The
clotswere incubated for2hoursat 100%humidity. Forfixation,
clots were given three washes (for 40minutes each) with
67mM sodium cacodylate, pH 7.4 and an overnight wash in
2% glutaraldehyde in sodium cacodylate buffer. Samples were
dehydrated using a series of acetone washes and dried in a
critical point drier. The clots were mounted on SEM stubs,
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coated with a 4nm layer of iridium and viewed and photo-
graphed at 10,000 magnification using a SU8230 scanning
electron microscope (Hitachi; Maidenhead, UK) operating at
10kV. Five images per sample were acquired and they were
analyzedwith Adobe Photoshop (Adobe Systems; San Jose, CA,
United States); the diameters of 50 fibers per picture were
measured. The images were adjusted for brightness and
contrast and cropped.
Turbidimetric Fibrin Clot Lysis Assays in a Purified
System
To test the influence of the interaction betweenMg2þ and PAI-
1 on lysis time, turbidimetric fibrin clot lysis assays were
performed in a purified system that includedexogenous PAI-1.
A buffer (50mM Tris, 100mM NaCl, pH 7.4) was added to the
wells of a 96-well plate, followed by fibrinogen (depleted in
plasminogen, von Willebrand factor and fibronectin; Enzyme
Research Laboratories, Swansea, UK). MgCl2 was then added
followed by PAI-1 (Sigma-Aldrich; Gillingham, UK), then plas-
minogen (Stratech; Ely, UK) and tPA, and finally CaCl2 and
thrombin. Final concentrations were 0.5mg/mL fibrinogen,
2.5mM CaCl2, 0.05 U/mL thrombin, 3.12 µg/mL plasminogen,
39 ng/mL t-PA, 0 or 200 ng/mL PAI-1, and 0 to 3.2mMMgCl2.
Absorbance at 340nm was read with a Multiskan FC plate
reader every 12 seconds at 37°C. Clot lysis was calculated from
the resultant data using Prism 7.0 (GraphPad Software).
Data Analysis and Representation
Distribution of the data was confirmed with normality tests
and statistical differences between groups analyzed using
either one-way analysis of variance or multiple Student’s t-
tests or, for continuous parameters, using Pearson’s correla-
tion test. Significance thresholdwas set at p0.05. Statistical
analyses were performed and graphs were generated with
Prism 7.0 (GraphPad Software). Data are represented as
mean standard deviation.
Results
Demographic Information and Measure of Plasma
Concentrations of Different Molecules
Alterations in fibrin clot formation and lysis parameters
were assessed between individuals with T1DM and con-
trols. Demographic information was collected and the plas-
ma concentrations of triglycerides, cholesterol, LDL, HDL,
cholesterol ratio, HbA1c, HSA, and fibrinogen were mea-
sured as presented in ►Table 1. The two study groups were
matched for age and sex. The T1DM group had a higher BMI
(p¼0.0206), but no differences were observed in lipid
concentrations (triglycerides, cholesterol, LDL, HDL, and
cholesterol ratio). HbA1c was higher in the T1DM group
(p<0.0001) compared with controls, while HSA concentra-
tions were lower in the T1DM group (p¼0.0269) compared
Table 1 Demographic information and measures of plasma concentrations of relevant molecules for the clinical cohort
Controls (n¼47) Subjects with T1DM (n¼45) Statistical significance
Mean Standard deviation Mean Standard deviation p-values
Age (years) 24.3 6.2 26.3 6.8 0.1436
Sex (% of male) 55 – 58 – 0.8145
Height (m) 1.73 0.09 1.73 0.10 0.7594
BMI (kg/m2) 23.0 2.9 24.6 3.6 0.0206
Numbers of smoking individuals 2 – 13 – –
Numbers of macrovascular events 0 – 0 – –
Numbers of microvascular events 0 – 1 – –
Numbers of individuals with familial
history of autoimmunity
12 – 16 – –
Numbers of individuals with familial
history of Huntington’s disease
16 – 9 – –
Diabetes duration (mo) – – 124.8 101.8 –
HbA1c (mmol/mol) 34.6 3.1 72.6 17.6 <0.0001
HbA1c (%) 5.3 0.3 8.8 1.6 –
Triglyceride (mmol/L) 0.9574 0.307 0.8953 0.3518 0.3738
Cholesterol (mmol/L) 4.23 0.9065 4.445 0.6899 0.2072
LDL (mmol/L) 2.364 0.7551 2.488 0.5446 0.3858
HDL (mmol/L) 1.455 0.3764 1.551 0.4137 0.2529
Cholesterol/HDL ratio 3.019 0.6943 2.964 0.6617 0.7045
HSA concentration (g/L) 45.9 2.4 44.7 2.6 0.0269
Fibrinogen (mg/mL) 2.28 0.47 2.39 0.46 0.2425
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; HSA, human serum albumin; LDL, low density
lipoprotein; T1DM, type-1 diabetes mellitus.
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with controls and fibrinogen concentrations were compa-
rable between groups.
Fibrin Clot Formation and Lysis Parameters and Fibrin
Clot Ultrastructure
Validated turbidimetric fibrin clot formation and lysis
assays13,14 were performed on the plasma samples taken
from the T1DM and the control groups. The maximum absor-
bance of the fibrin clots did not differ between the T1DM and
control groups (►Fig. 1A). Lysis time was longer in the T1DM
group comparedwith the control group (p¼0.0273,►Fig. 1B).
No differences between males and females were found in the
T1DM group for maximum absorbance or lysis time, either in
individuals of all ages (►Fig. 1C,D) or in lysis time in individu-
als under 30 years old (►Fig. 1E). SEM experiments were
performedonpooledplasma (fromboth sexes) from the T1DM
and the control groups and the average diameter of fibrin
fibers were measured (►Fig. 2). The fiber diameter was not
statistically significantly altered in the T1DMgroup compared
with the control group.
PAI-1 Concentration in Subjects with T1DM and
Correlation with Lysis Time and Plasma Magnesium
Concentration
The plasma PAI-1 concentration was measured in the T1DM
and control groups and potential associations with lysis time
Fig. 1 Comparison of fibrin clot parameters in plasma samples from individuals with T1DM and controls. (A, B) Fibrin clot parameters were compared
between controls and T1DM, (C, D) between all males and females with T1DM and (E) between males and females under 30 years old with T1DM. Clot
formation experiments were performed in plasma (n¼ 47 for subjects with T1DMand n¼ 45 for controls). Plasmawas diluted six-fold in buffer and the final
concentrationsof reagentsusedwere:7.5mMCaCl2, 0.03U/mL thrombin, and20.8ng/mL tPA. (A,C)Maximumabsorbanceand (B,D,E) and lysis timewere
measured.Maximumabsorbancewas not different between the control and the T1DMgroups. Lysis timewas increased in individuals with T1DMcompared
with controls (p¼ 0.0273). Maximum absorbance and lysis time were not different when comparing all males and females with T1DM or only those under
30 years old. Statistical significance is indicated with ns where p> 0.05 and  where p< 0.001.
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and plasma magnesium concentrations were examined
(►Fig. 3). The PAI-1 concentration was lower in the T1DM
group compared with the control group (p¼0.0232), and
PAI-1 concentration was found to be positively associated
with lysis time (p¼0.0023).
Relationship between Total Plasma Concentrations of
Magnesium and Clot Formation and Lysis Parameters
in Subjects with T1DM
In a previous study, total plasma magnesium was measured
in plasma taken from subjects with T1DM and age-matched
Fig. 2 Comparison of fibrin fiber diameters in plasma from individuals with T1DM and controls. The clots were formed in duplicate with 45 µL of
plasma (pooled from six random samples) diluted two-fold in buffer and 5 µL of 25mM CaCl2 and 5 U/mL thrombin; five images were taken per
clot and 50 fibers were measured per image. (A) Representative SEM images of a clot formed in plasma from the control group or from the T1DM
group. (B) Average diameters of fibrin fibers in T1DM and control groups. No difference in the thickness of fibers was observed between the
controls and the subjects with T1DM. ns indicates that p> 0.05. The images were adjusted for brightness and contrast and cropped.
Fig. 3 Relationship between lysis time and the plasma concentrations of PAI-1 in T1DM and controls. (A) Comparison of plasma PAI-1
concentrations between controls and subjects with T1DM. (B) Comparison of PAI-1 concentration between males and females with T1DM. (C)
Relationship between lysis time and plasma PAI-1 concentration. PAI-1 concentration was lower in individuals with T1DM (p¼ 0.032), but there
was no difference between males and females with T1DM. Lysis time was positively correlated with PAI-1 concentration (p¼ 0.0023). ns indicates
that p> 0.05 and  where p< 0.05.
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controls using inductively coupled plasma-mass spectrome-
try (►Fig. 4).9 The mean total plasma magnesium concen-
tration was lower in the T1DM group compared with the
control group when assessing both sexes together
(p<0.0001) or when looking separately at male subjects
(p¼0.0076) or female subjects (p<0.0001). The total plasma
magnesium concentration was lower in females with T1DM
than males with T1DM (p¼0.0329). Potential associations
between total plasma magnesium concentration and fibrin
clot parameters or PAI-1 were then assessed (►Fig. 5).
Negative correlations were found between total plasma
magnesium concentration and maximum absorbance
(p¼0.0215) and between total plasma magnesium concen-
tration and lysis (p¼0.0464). However, the PAI-1 concentra-
tion did not correlate with the plasma magnesium
concentration.
Influence of Mg2þ-PAI-1 Interaction on Lysis Time
To assess the influence of theMg2þ-PAI-1 interaction on lysis
time, turbidimetric fibrin clot lysis assays were performed in
a purified system that included PAI-1 in the presence of 0 to
3.2mM Mg2þ (►Fig. 6). Lysis time was found to decrease
with increasing Mg2þ concentrations (p¼0.0004). The lysis
time obtained in the presence of each Mg2þ concentration
did not significantly differ except between 3.2mMMg2þ and
the other Mg2þ concentrations, where it was found to be
lower. In the presence of PAI-1 and 3.2mM Mg2þ, the lysis
time was not significantly altered compared with the ab-
sence of PAI-1.
Discussion
Individuals with T1DM are known to be deficient in magne-
sium and to have an elevated thrombosis risk. Therefore, we
wanted to assess whether the plasma Mg2þ concentration
relates to fibrin clot formation and lysis as induced by the
addition of thrombin, Ca2þ, and tPA. To this end, clinical
samples from individuals with T1DM and controls were
examined. Both groups were matched in age and sex. The
plasmaHSAconcentrationwas reduced in subjectswith T1DM
compared with the controls, which may be a result of insulin
deficiency.15 Insulin deficiency has also been associated with
increased fibrinogen synthesis, probably as an acute-phase
response, and indeed a slight but not significant increase in
plasmafibrinogen concentrationwasobserved.15 In a studyby
Agren et al, fibrinogen concentration has previously been
reported to be lower in individuals with T1DM compared
with healthy controls, but this work was performed on an
older cohort; the mean age of individuals with T1DM was
44 years in their study comparedwith 26 years in our study.16
Fig. 4 Comparison of total plasma magnesium concentration between individuals with T1DM and controls. Comparison of total plasma
magnesium concentration between individual with T1DM and controls in (A) both sexes, (B) males, and (C) females. (D) Comparison of total
plasma magnesium concentration between males and females with T1DM. Total plasma magnesium concentrations were lower in subjects with
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No difference was observed in fibrin fiber thickness be-
tween clots formed in pooled samples taken from individuals
with T1DM and those taken from controls. The turbidimetric
assay revealed that clots formed in plasma from individuals
with T1DM exhibited an increase in lysis time, but an un-
changed maximum absorbance compared with controls. A
previous study by Tehrani et al reported that no differences in
fibrinclotproperties couldbeseenbetweenmales andfemales
(aged 20 years or above) with T1DM, but those females with
T1DM aged less than 30 years had less permeable fibrin clots
and prolonged lysis times than age-matched males with
T1DM.17 This study did not compare clot properties between
individuals with T1DM and healthy controls.17 In the results
presented here, no differences between males and females
were observed, either when considering all the subjects with
T1DM or only those aged less than 30 years old. The study by
Agren et al also found no sex-specific differences in lysis time
between individuals with T1DM and controls.16However, the
study also reported shorter lysis times in individuals with
T1DM, which they explained by the fibrin clots being more
resistant to fibrinolysis (with more antiplasmin incorporated
in thefibrin clots despite lower plasma concentrations), while
the fibrinolytic potential of the plasma simultaneously in-
creased (marked by a reduced activity of PAI-1) and the
fibrinogen concentration was reduced.16 The difference be-
tween these results and the lysis time observed in our study
could be explained by the age of the patients (mean age
44 years in the Agren et al study and 24 years in this study)
and the treatment regimen at the time of blood collection (in
the Agren et al study, some patients were on ACE inhibitors,
statins, and estrogens, while our study excluded them), result-
ing in unchanged fibrinogen concentrations between our
T1DM cohort and control groups.
It was found that the plasma PAI-1 concentration was
reduced in the T1DM group compared with the controls,
which is consistent with previous observations showing
reduced or similar PAI-1 levels in T1DM compared with
controls.14,16 However, this is contrary to a study by Adly
et al, which reported elevated concentrations of PAI-1 in
children and adolescents with T1DM—especially in those
with microvascular complications—compared with con-
trols.18 This difference may be explained by the presence
of complications in that study, whereas patients in our study
had no clinically significant diabetes-associated complica-
tions. PAI-1 concentration positively correlated to lysis time
in our study, which is in accordwith its known importance in
regulating the fibrinolytic process.19,20
Whenexamining potential associations between total plas-
ma magnesium concentration and clot parameters, magne-
sium concentration was found to negatively correlate with
maximumabsorbanceandwith lysis time. Thus, thedeficiency
of magnesium found in the subjects with T1DM could poten-
tially directly result in increased maximum absorbance and
lysis time. Fibrinogen concentration was similar in T1DM and
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control groups and therefore cannot explain the significant
difference observed in maximum absorbance. The reduced
PAI-1 concentration in the T1DM group should result in
increased tissue plasminogen activator activity and enhanced
lysis, which is in opposition to our results. Thus, another factor
must explain the increased in lysis time observed in the T1DM
group. The negative correlation between total plasmamagne-
sium concentration and lysis time may partly provide an
explanation for this phenomenon.
Several studies have previously examined the effects of
Mg2þ on coagulation; however, some of the reported results
are contradictory. This is likely because the effects of Mg2þ
on fibrin clot formation and lysis are complex, with Mg2þ
having the ability to influence many different interactions
(both positively and negatively). In addition, in vitro fibrin
clotting can be initiated at different points within the
coagulation cascade. This is why in some studies initiation
of clotting at certain points in the cascade may mean that
parts of the cascade are bypassed; thus, the effect of Mg2þ
may differ depending on the experimental design. In our
assays, fibrin clot formation was triggered by the addition of
thrombin and Ca2þ. This implicates both the intrinsic and
extrinsic pathway of the coagulation cascade as thrombin
does not only cleave fibrinogen into fibrin, but it also
activates proteins participating in prothrombin activation,
including factor VII, factor VIII, factor V, and factor XI. Thus,
while the addition of thrombin to initiate coagulation signi-
fies that the thrombin concentration will be the same when
the clot starts to form, differences in plasma composition
will affect how prothrombin is activated or inhibited and so
thrombin concentration during later stages of clot formation
and during clot lysis, which has been shown previously to
affect fibrin clot parameters.21 Nevertheless, our assay is
limited by the absence of the endothelium, which prevents
some interactions from taking place (in particular with the
absence of the release of tissue factor and phospholipids).
Another important factor in the fibrin clot experiments is the
concentration of Mg2þ used, as Mg2þ potentiates interactions
at lower concentration (<10mM), while at high concentra-
tions, (>10mM, not physiological) it competes with Ca2þ
and interferes with its role as a cofactor.7,22 In our assay an
excess of Ca2þ was added while no additional Mg2þ was
added, thus preventing Mg2þ competition with Ca2þ from
becoming relevant. Due to the lack of specific indicators for
Mg2þ, it is impossible to know the amount of Mg2þ ionized
during recalcification of citrated plasma. Despite this, the
dissociation constants of both Ca2þ and Mg2þ binding to
citrate (in the same buffer; 5mM Tris, 5mM MES, 5mM
PIPES, pH 6.0) have been measured. Under these conditions,
it was shown that Ca2þ binds citrate with a Kd of 66 µM
while Mg2þ binds citrate with a Kd of 157 µM, showing Mg2þ
to possess a lower affinity than Ca2þ for citrate.23 Thus, as a
large excess of CaCl2 is added into the diluted citrated
plasma, it can be expected that most Mg2þ (>95%) will be
ionized under the experimental conditions.
It has been shown previously that Mg2þ (0.5–1mM)
accelerates the activation of factor X by activated factor IX
(in the presence of activated factor VIII, phospholipids and
Ca2þ) as well as the activation of factor IX and of factor X by
the activated factor VIIa-tissue factor complex.5,24 Further-
more, the addition of Mg2þ in plasma from healthy subjects
has been shown to have various effects on clotting time
depending on the type of plasma and magnesium concen-
trations used in the studies and on the method by which
clotting was induced.22,24,25 Mg2þ is also involved in anti-
coagulatory processes as 0.6mM Mg2þ potentiates the inac-
tivation of activated factor V by activated protein C.26 In
addition, increasing Mg2þ concentrations added to whole
blood (0–8mM Mg2þ, no clotting occurred with 10mM
Mg2þ) have been shown to reduce the spontaneous fibrin
lysis time, whichwas hypothesized to be due to its inhibition
of PAI-1 in the presence of thrombin and vitronectin.22 Thus,
magnesium inhibition of PAI-1 could result in an increase in
tPA activity, an increase in clot lysis and a shorter lysis time.
This could explain why low plasma magnesium concentra-
tions are correlated with increased lysis time. To assess the
effect ofMg2þ-PAI-1 interactions on lysis time,weperformed
a turbidimetric assay in a purified system incorporating PAI-
1 and differentMg2þ concentrations. The results confirmed a
shortening of the lysis time by Mg2þ. The presence of supra-
physiological concentrations ofMg2þ (ca. 3.2mM) complete-
ly inhibited PAI-1 activity. However, the inhibitory effect was
subtle at physiologicalMg2þ concentrations (ca. 0.6–1.0mM)
and soMg2þ-inhibition of PAI-1 is unlikely to fully justify the
longer lysis time found in the T1DM group. Another un-
known mechanism is most likely involved in further pro-
longing lysis time.
Fig. 6 Effects of Mg2þ- PAI-1 interactions on fibrin clot lysis. Turbi-
dimetric assays were performed in a purified system made of buffer
(50mM Tris, 100mM NaCl, pH 7.4), 0.5mg/mL fibrinogen, 2.5mM
CaCl2, 0.05 U/mL thrombin, 3.12 µg/mL plasminogen, 39 ng/mL t-PA,
0 or 200 ng/mL PAI-1, and 0 to 3.2mM MgCl2; the lysis time was
calculated. Addition of 0.1 to 3.2mM Mg2þ shortened lysis time
(p¼ 0.0004). In the presence of 3.2mMMg2þ and PAI-1, lysis time was
not significantly different to its value in the absence of PAI-1. ns
indicates that p> 0.05,  where p< 0.01, and  where p< 0.001.
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Alterations in clot lysis may also affect clot formation and
explain the correlation between total plasma magnesium
concentration and clot maximum absorbance; however, if
this is the case, this did not translate to a difference in
maximum absorbance in the T1DM group compared with
the controls. Despite females with T1DM having higher risk
of thrombosis than males with T1DM, no difference be-
tween the sexes could be seen in lysis time or clot time.17,27
However, the total plasma magnesium concentration is
lower in females with T1DM than in males with T1DM, so
alterations in clot formation and lysis caused by magnesium
may be more common in females; this correlates with the
higher thrombotic risk observed in females (compared with
males). It is of interest to note that magnesium supplemen-
tation in individuals with T1DM has been shown to de-
crease the risk of developing complications associated with
diabetes, including cardiovascular disease.27
Conclusion
In this study, we demonstrate that plasma magnesium
concentration negatively associates with both fibrin clot
density (maximum absorbance) and with lysis time in
subjects with T1DM and controls. Given that Mg2þ is a
known regulator of multiple proteins that facilitate clot
formation and lysis, this observation may help to explain
the higher risk of thrombosis observed in those with T1DM,
as such individuals have lower plasma magnesium concen-
trations than those without diabetes. Collectively, the
results presented here highlight the importance of
Mg2þ for normal clot formation and lysis and lends support
to the hypothesis that lowered plasma Mg2þ levels in
T1DM contribute to the development of thrombotic
complications.
What is known about this topic?
• Individuals with T1DM are at a higher risk of develop-
ing microvascular complications and long-term vascu-
lar diseases.
• Plasma magnesium levels are lower in those with
T1DM compared to individuals without diabetes.
• Magnesium is a known regulator of coagulation and
fibrin network formation.
What does this paper add?
• A lowered plasma magnesium concentration is associ-
atedwith increased fibrin clot density and delayed clot
lysis.
• Mg2þ-dependent inhibition of PAI-1 contributes to this
phenomenon but is unlikely to be the only mechanism
by which Mg2þ influences fibrin clot formation and
lysis.
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